Cardiovascular risk and aging: the need for a more comprehensive understanding

Ljiljana Trtica Majnarić; Zvonimir Bosnić; Tomislav Kurevija; Thomas Wittlinger

doi:10.11909/j.issn.1671-5411.2021.06.004

Volume 18 Issue 6

Jun. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Geriatric Cardiology > 2021 > 18(6): 462-478

Please cite this article as: Majnarić LT, Bosnić Z, Kurevija T, Wittlinger T. Cardiovascular risk and aging: the need for a more comprehensive understanding. J Geriatr Cardiol 2021; 18(6): 462−478. DOI: 10.11909/j.issn.1671-5411.2021.06.004

Citation:

Please cite this article as: Majnarić LT, Bosnić Z, Kurevija T, Wittlinger T. Cardiovascular risk and aging: the need for a more comprehensive understanding. J Geriatr Cardiol 2021; 18(6): 462−478. DOI: 10.11909/j.issn.1671-5411.2021.06.004

Citation:

PDF( 1776 KB)

Cardiovascular risk and aging: the need for a more comprehensive understanding

doi: 10.11909/j.issn.1671-5411.2021.06.004

Ljiljana Trtica Majnarić^{1, 2, 3, 4},
Zvonimir Bosnić^{1, 2, 3, 4},
Tomislav Kurevija^{1, 2},
Thomas Wittlinger^{5
,
,}

1.
Faculty of Medicine, University Josip Juraj Strossmayer, Osijek, Croatia
2.
Department of Internal Medicine, Family Medicine and the History of Medicine, Osijek, Croatia
3.
Faculty of Dental Medicine, University Josip Juraj Strossmayer, Osijek, Croatia
4.
Department of Public Health, Osijek, Croatia
5.
Asklepios Harzkliniken, Department of Cardiology, Goslar, Germany

More Information

Corresponding author: dr.wittlinger@gmx.de
Available Online: 2021-06-22
Publish Date: 2021-06-22

Abstract

FullText(HTML)

References(107)

References

[1]	Winslow CE. Public health at the crossroads. 1926. Am J Public Health 1999; 89: 1645−1648. doi: 10.2105/AJPH.89.11.1645
[2]	KAGAN A, DAWBER TR, KANNEL WB, et al. The Framingham study: a prospective study of coronary heart disease. Fed Proc 1962; 21: 52−57.
[3]	Graham IM. The importance of total cardiovascular risk assessment in clinical practice. Eur J Gen Pract 2006; 12: 148−155. doi: 10.1080/13814780600976282
[4]	von Eckardstein A. Is there a need for novel cardiovascular risk factors? Nephrol Dial Transplant 2004; 19: 761−765. doi: 10.1093/ndt/gfh111
[5]	Damen JA, Hooft L, Schuit E, et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ 2016; 353: i2416. doi: 10.1136/bmj.i2416
[6]	Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935−2959. doi: 10.1016/j.jacc.2013.11.005
[7]	Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315−2381. doi: 10.1093/eurheartj/ehw106
[8]	Studziński K, Tomasik T, Krzysztoń J, et al. Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: an overview of systematic reviews. BMC Cardiovasc Disord 2019; 19: 11. doi: 10.1186/s12872-018-0990-2
[9]	Uchmanowicz I, Hoes A, Perk J, et al. Optimising implementation of European guidelines on cardiovascular disease prevention in clinical practice: what is needed? Eur J Prev Cardiol 2020; 2: 2047487320926776. doi: 10.1177/2047487320926776
[10]	Stewart J, Manmathan G, Wilkinson P. Primary prevention of cardiovascular disease: a review of contemporary guidance and literature. JRSM Cardiovasc Dis 2017; 6: 2048004016687211. doi: 10.1177/2048004016687211
[11]	Leening MJG, Cook NR, Ridker PM. Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease? Eur Heart J 2017; 38: 1542−1547. doi: 10.1093/eurheartj/ehw287
[12]	Leening MJG, Ikram MA. Primary prevention of cardiovascular disease: the past, present and future of blood pressure- and cholesterol-lowering treatments. PLoS Med 2018; 15: e1002539. doi: 10.1371/journal.pmed.1002539
[13]	D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743−753. doi: 10.1161/CIRCULATIONAHA.107.699579
[14]	Welcome to the QRISK^®2-2017 Cardiovascular Disease Risk Calculator Home Page. https://qrisk.org/2017 (accessed Jan 1, 2021).
[15]	Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 2005; 365: 434−441. doi: 10.1016/S0140-6736(05)70240-3
[16]	Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol 2009; 54: 1209−1227. doi: 10.1016/j.jacc.2009.07.020
[17]	Steyerberg EW, van der Ploeg T, Van Calster B. Risk prediction with machine learning and regression methods. Biom J 2014; 56: 601−606. doi: 10.1002/bimj.201300297
[18]	Montgomery AA, Fahey T, Peters TJ, et al. Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomized controlled trial. BMJ 2000; 320: 686−690. doi: 10.1136/bmj.320.7236.686
[19]	Trtica-Majnarić L, Včev A. In Designing Computer-Based Clinical Guidelines Decision Support by a Clinician; Holzinger A, Pasi G, Eds. ; Human-Computer Interaction and Knowledge Discovery in Complex, Unstructured, Big Data. HCI-KDD 2013. Springer, Berlin, Heidelberg, 2013; Lecture Notes in Computer Science, 7947.
[20]	Wilson PW, Pencina M, Jacques P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008; 1: 92−97. doi: 10.1161/CIRCOUTCOMES.108.831198
[21]	Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987−1003. doi: 10.1016/S0195-668X(03)00114-3
[22]	van Bussel EF, Richard E, Busschers WB, et al. A cardiovascular risk prediction model for older people: development and validation in a primary care population. J Clin Hypertens (Greenwich) 2019; 21: 1145−1152. doi: 10.1111/jch.13617
[23]	Zethelius B, Berglund L, Sundström J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107−2116. doi: 10.1056/NEJMoa0707064
[24]	Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008; 29: 932−940. doi: 10.1093/eurheartj/ehn018
[25]	Cooney MT, Selmer R, Lindman A, et al. Cardiovascular risk estimation in older persons: SCORE O. P. Eur J Prev Cardiol 2016; 23: 1903−1103. doi: 10.1177/2047487316663546
[26]	Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation 2020; 141: e139−e596. doi: 10.1161/CIR.0000000000000757
[27]	Causes of death statistics-people over 65 Home Page. https://ec.europa.eu/eurostat/statistics (accessed Jan 1, 2021).
[28]	Mensah GA, Wei GS, Sorlie PD, et al. Decline in cardiovascular mortality: possible causes and implications. Circ Res 2017; 120: 366−380. doi: 10.1161/CIRCRESAHA.116.309115
[29]	Prentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol 2006; 35: 93−99. doi: 10.1093/ije/dyi272
[30]	North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res 2012; 110: 1097−1108. doi: 10.1161/CIRCRESAHA.111.246876
[31]	Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410−1422. doi: 10.1038/nm.2538
[32]	Tuttle CSL, Maier AB. Towards a biological geriatric assessment. Exp Gerontol 2018; 107: 102−107. doi: 10.1016/j.exger.2017.09.017
[33]	Martín-Fernández B, Gredilla R. Mitochondria and oxidative stress in heart aging. Age (Dordr) 2016; 38: 225−238. doi: 10.1007/s11357-016-9933-y
[34]	Nakou ES, Parthenakis FI, Kallergis EM, et al. Healthy aging and myocardium: a complicated process with various effects in cardiac structure and physiology. Int J Cardiol 2016; 209: 167−175. doi: 10.1016/j.ijcard.2016.02.039
[35]	Mancuso P, Bouchard B. The impact of aging on adipose function and adipokine synthesis. Front Endocrinol (Lausanne) 2019; 10: 137. doi: 10.3389/fendo.2019.00137
[36]	Mulligan AA, Lentjes MAH, Luben RN, et al. Changes in waist circumference and risk of all-cause and CVD mortality: results from the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) cohort study. BMC Cardiovasc Disord 2019; 19: 238. doi: 10.1186/s12872-019-1223-z
[37]	Akintoye E, Briasoulis A, Afonso L. Biochemical risk markers and ten-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification. Am Heart J 2017; 193: 95−103. doi: 10.1016/j.ahj.2017.08.002
[38]	Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380: 37−43. doi: 10.1016/S0140-6736(12)60240-2
[39]	Onder G, Palmer K, Navickas R, et al. Time to face the challenge of multimorbidity. A European perspective from the joint action on chronic diseases and promoting healthy ageing across the life cycle (JA-CHRODIS). Eur J Intern Med 2015; 26: 157−159. doi: 10.1016/j.ejim.2015.02.020
[40]	Calderón-Larrañaga A, Vetrano DL, Ferrucci L, et al. Multimorbidity and functional impairment-bidirectional interplay, synergistic effects and common pathways. J Intern Med 2019; 285: 255−271. doi: 10.1111/joim.12843
[41]	Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011; 10: 430−439. doi: 10.1016/j.arr.2011.03.003
[42]	Buddeke J, Bots ML, van Dis I, et al. Comorbidity in patients with cardiovascular disease in primary care: a cohort study with routine healthcare data. Br J Gen Pract 2019; 69: e398−e406. doi: 10.3399/bjgp19X702725
[43]	Willadsen TG, Siersma V, Nicolaisdóttir DR, et al. Multimorbidity and mortality: a 15-year longitudinal registry-based nationwide Danish population study. J Comorb 2018; 8: 2235042X18804063. doi: 10.1177/2235042X18804063
[44]	Forman DE, Maurer MS, Boyd C, et al. Multimorbidity in older adults with cardiovascular disease. J Am Coll Cardiol 2018; 71: 2149−2161. doi: 10.1016/j.jacc.2018.03.022
[45]	Lu Y, Hajifathalian K, Ezzati M, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet 2014; 383: 970−983. doi: 10.1016/S0140-6736(13)61836-X
[46]	Abdelhafiz AH, Brown SH, Bello A, et al. Chronic kidney disease in older people: physiology, pathology or both? Nephron Clin Pract 2010; 116: c19−c24. doi: 10.1159/000314545
[47]	Marengoni A, Roso-Llorach A, Vetrano DL, et al. Patterns of multimorbidity in a population-based cohort of older people: sociodemographic, lifestyle, clinical, and functional differences. J Gerontol A Biol Sci Med Sci 2020; 75: 798−805. doi: 10.1093/gerona/glz137
[48]	Cigolle CT, Langa KM, Kabeto MU, et al. Geriatric conditions and disability: the Health and Retirement Study. Ann Intern Med 2007; 147: 156−164. doi: 10.7326/0003-4819-147-3-200708070-00004
[49]	Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908: 244−254. doi: 10.1111/j.1749-6632.2000.tb06651.x.
[50]	Clerencia-Sierra M, Ioakeim-Skoufa I, Poblador-Plou B, et al. Do centenarians die healthier than younger elders? A comparative epidemiological study in Spain. J Clin Med 2020; 9: 1563. doi: 10.3390/jcm9051563
[51]	Franceschi C, Garagnani P, Morsiani C, et al. The continuum of aging and age-related diseases: common mechanisms but different rates. Front Med (Lausanne) 2018; 5: 61. doi: 10.3389/fmed.2018.00061
[52]	Leening MJG, Ikram MA. Primary prevention of cardiovascular disease: the past, present, and future of blood pressure-and cholesterol-lowering treatments. PLoS Med 2018; 15: e1002539. doi: 10.1371/journal.pmed.1002539
[53]	Whelton SP, Roy P, Astor BC, et al. Elevated high-sensitivity C-reactive protein as a risk marker of the attenuated relationship between serum cholesterol and cardiovascular events at older age. The ARIC Study. Am J Epidemiol 2013; 178: 1076−1084. doi: 10.1093/aje/kwt086
[54]	Lind L, Sundström J, Ärnlöv J, et al. Impact of aging on the strength of cardiovascular risk factors: a longitudinal study over 40 years. J Am Heart Assoc 2018; 7: e007061. doi: 10.1161/JAHA.117.007061
[55]	Saeed A, Nambi V, Sun W, et al. Short-term global cardiovascular disease risk prediction in older adults. J Am Coll Cardiol 2018; 71: 2527−2536. doi: 10.1016/j.jacc.2018.02.050
[56]	Rosso AL, Eaton CB, Wallace R, et al. Combined impact of geriatric syndromes and cardiometabolic diseases on measures of functional impairment. J Gerontol A Biol Sci Med Sci 2011; 66: 349−354. doi: 10.1093/gerona/glq230
[57]	Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146−M156. doi: 10.1093/gerona/56.3.M146
[58]	Fried LP, Xue QL, Cappola AR, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. J Gerontol A Biol Sci Med Sci 2009; 64: 1049−1057. doi: 10.1093/gerona/glp076
[59]	Cesari M, Calvani R, Marzetti E. Frailty in older persons. Clin Geriatr Med 2017; 33: 293−303. doi: 10.1016/j.cger.2017.02.002
[60]	Frisoli A Jr, Ingham SJ, Paes ÂT, et al. Frailty predictors and outcomes among older patients with cardiovascular disease: data from Fragicor. Arch Gerontol Geriatr 2015; 61: 1−7. doi: 10.1016/j.archger.2015.03.001
[61]	Soysal P, Stubbs B, Lucato P, et al. Inflammation and frailty in the elderly: a systematic review and meta-analysis. Ageing Res Rev 2016; 31: 1−8. doi: 10.1016/j.arr.2016.08.006
[62]	Villareal DT, Apovian CM, Kushner RF, et al. Obesity in older adults: technical review and position statement of the American Society for Nutrition and Naaso, the Obesity Society. Am J Clin Nutr 2005; 82: 923−934. doi: 10.1093/ajcn/82.5.923
[63]	Elagizi A, Kachur S, Lavie CJ, et al. An overview and update on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis 2018; 61: 142−150. doi: 10.1016/j.pcad.2018.07.003
[64]	Calvani R, Picca A, Marini F, et al. The “BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons” (BIOSPHERE) study: rationale, design and methods. Eur J Intern Med 2018; 56: 19−25. doi: 10.1016/j.ejim.2018.05.001
[65]	Charnigo R, Guglin M. Obesity paradox in heart failure: statistical artifact, or impetus to rethink clinical practice? Heart Fail Rev 2017; 22: 13−23. doi: 10.1007/s10741-016-9577-0
[66]	Banack HR, Kaufman JS. Does selection bias explain the obesity paradox among individuals with cardiovascular disease? Ann Epidemiol 2015; 25: 342−349. doi: 10.1016/j.annepidem.2015.02.008
[67]	Anker D, Santos-Eggimann B, Zwahlen M, et al. Blood pressure in relation to frailty in older adults: a population-based study. J Clin Hypertens (Greenwich) 2019; 21: 1895−1904. doi: 10.1111/jch.13722
[68]	Calderón-Larrañaga A, Vetrano DL, Ferrucci L, et al. Multimorbidity and functional impairment-bidirectional interplay, synergistic effects and common pathways. J Intern Med 2019; 285: 255−271. doi: 10.1111/joim.12843
[69]	Goldberger AL, Peng CK, Lipsitz LA. What is physiologic complexity and how does it change with aging and disease? Neurobiol Aging 2002; 23: 23−26. doi: 10.1016/S0197-4580(01)00266-4
[70]	Cohen AA, Milot E, Li Q, et al. Detection of a novel, integrative aging process suggests complex physiological integration. PloS One 2015; 10: e0116489. doi: 10.1371/journal.pone.0116489
[71]	Knauff M, Wolf AG. Complex cognition: the science of human reasoning, problem-solving, and decision-making. Cogn Process 2010; 11: 99−102. doi: 10.1007/s10339-010-0362-z
[72]	Raberin A, Connes P, Barthélémy JC, et al. Role of gender and physical activity level on cardiovascular risk factors and biomarkers of oxidative stress in the elderly. Oxid Med Cell Longev 2020; 2020: 1315471. doi: 10.1155/2020/1315471
[73]	Liang Y, Vetrano DL, Qiu C. The role of biological age in the management of hypertension in old age: does SPRINT tell the whole story? Int J Cardiol 2016; 222: 699−700. doi: 10.1016/j.ijcard.2016.08.085
[74]	Orkaby AR, Onuma O, Qazi S, et al. Preventing cardiovascular disease in older adults: one size does not fit all. Cleve Clin J Med 2018; 85: 55−64. doi: 10.3949/ccjm.85a.16119
[75]	Todd OM, Wilkinson C, Hale M, et al. Is the association between blood pressure and mortality in older adults different with frailty? A systematic review and meta-analysis. Age Ageing 2019; 48: 627−635. doi: 10.1093/ageing/afz072
[76]	Vetrano DL, Rizzuto D, Calderón-Larrañaga A, et al. Trajectories of functional decline in older adults with neuropsychiatric and cardiovascular multimorbidity: a Swedish cohort study. PLoS Med 2018; 15: e1002503. doi: 10.1371/journal.pmed.1002503
[77]	Dhana K, Koolhaas CM, van Rossum EF, et al. Metabolically healthy obesity and the risk of cardiovascular disease in the elderly population. PloS One 2016; 11: e0154273. doi: 10.1371/journal.pone.0154273
[78]	Flegal KM, Ioannidis JPA. The obesity paradox: a misleading term that should be abandoned. Obesity (Silver Spring) 2018; 26: 629−630. doi: 10.1002/oby.22140
[79]	Marcus J, Sarnak MJ, Menon V. Homocysteine lowering and cardiovascular disease risk: lost in translation. Can J Cardiol 2007; 23: 707−710. doi: 10.1016/S0828-282X(07)70814-0
[80]	Yıldırım P, Ljiljana MT, Bosnić Z, et al. Complexity and non-linearity of cardiovascular risk factors in older patients with multimorbidity and reduced renal function. J Integr Cardiol Open Access 2020; 3: 1−11.
[81]	Sidey-Gibbons JAM, Sidey-Gibbons CJ. Machine learning in medicine: a practical introduction. BMC Med Res Methodol 2019; 19: 64. doi: 10.1186/s12874-019-0681-4
[82]	Seyhan AA, Carini C. Are innovation and new technologies in precision medicine paving a new era in patients centric care? J Transl Med 2019; 17: 114. doi: 10.1186/s12967-019-1864-9
[83]	Karmali KN, Lloyd-Jones DM, van der Leeuw J, et al. Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: a meta-analysis of individual participant data. PLoS Med 2018; 15: e1002538. doi: 10.1371/journal.pmed.1002538
[84]	Cowie MR, Blomster JI, Curtis LH, et al. Electronic health records to facilitate clinical research. Clin Res Cardiol 2017; 106: 1−9. doi: 10.1007/s00392-016-1025-6
[85]	Leening MJG, Cook NR, Ridker PM. Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease? Eur Heart J 2017; 38: 1542−1547. doi: 10.1093/eurheartj/ehw287
[86]	Onder G, Vetrano DL, Marengoni A, et al. Accounting for frailty when treating chronic diseases. Eur J Intern Med 2018; 56: 49−52. doi: 10.1016/j.ejim.2018.02.021
[87]	Finegold JA, Manisty CH, Goldacre B, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014; 21: 464−474. doi: 10.1177/2047487314525531
[88]	Giral P, Neumann A, Weill A, et al. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J 2019; 40: 3516−3525. doi: 10.1093/eurheartj/ehz458
[89]	Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older patients. Circ Res 2019; 124: 1045−1060. doi: 10.1161/CIRCRESAHA.118.313236
[90]	Leening MJ, Berry JD, Allen NB. Lifetime perspectives on primary prevention of atherosclerotic cardiovascular disease. JAMA 2016; 315: 1449−1450. doi: 10.1001/jama.2016.1654
[91]	Sniderman AD, Toth PP, Thanassoulis G, et al. Taking a longer term view of cardiovascular risk: the causal exposure paradigm. BMJ 2014; 348: g3047. doi: 10.1136/bmj.g3047
[92]	Allen NB, Siddique J, Wilkins JT, et al. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA 2014; 311: 490−497. doi: 10.1001/jama.2013.285122
[93]	Strandberg TE, Stenholm S, Strandberg AY, et al. The “obesity paradox, ” frailty, disability, and mortality in older men: a prospective, longitudinal cohort study. Am J Epidemiol 2013; 178: 1452−1460. doi: 10.1093/aje/kwt157
[94]	Franceschi C, Garagnani P, Morsiani C, et al. The continuum of aging and age-related diseases: common mechanisms but different rates. Front Med (Lausanne) 2018; 5: 61. doi: 10.3389/fmed.2018.00061
[95]	Beard JR, Officer A, de Carvalho IA, et al. The world report on ageing and health: a policy framework for healthy ageing. Lancet 2016; 387: 2145−2154. doi: 10.1016/S0140-6736(15)00516-4
[96]	Vetrano DL, Palmer KM, Galluzzo L, et al. Hypertension and frailty: a systematic review and meta-analysis. BMJ Open 2018; 8: e024406. doi: 10.1136/bmjopen-2018-024406
[97]	Boulton C, Wilkinson JM. Use of public datasets in the examination of multimorbidity: opportunities and challenges. Mech Ageing Dev 2020; 190: 111310. doi: 10.1016/j.mad.2020.111310
[98]	Guo Q, Lu X, Gao Y, et al. Cluster analysis: a new approach for identification of underlying risk factors for coronary artery disease in essential hypertensive patients. Sci Rep 2017; 7: 43965. doi: 10.1038/srep43965
[99]	Peterson ED. Machine learning, predictive analytics, and clinical practice: can the past inform the present? JAMA 2019; 322: 2283−2284. doi: 10.1001/jama.2019.17831
[100]	Weng C, Shah NH, Hripcsak G. Deep phenotyping: embracing complexity and temporality-towards scalability, portability, and interoperability. J Biomed Inform 2020; 105: 103433. doi: 10.1016/j.jbi.2020.103433
[101]	Hassaine A, Canoy D, Solares JRA, et al. Learning multimorbidity patterns from electronic health records using non-negative matrix factorisation. J Biomed Inform 2020; 112: 103606. doi: 10.1016/j.jbi.2020.103606
[102]	Zhao J, Zhang Y, Schlueter DJ, et al. Detecting time-evolving phenotypic topics via tensor factorization on electronic health records: cardiovascular disease case study. J Biomed Inform 2019; 98: 103270. doi: 10.1016/j.jbi.2019.103270
[103]	Majnarić-Trtica L, Vitale B, Martinis M. Is it time for a new approach in cardiovascular risk assessment? Period Biol 2008; 1110: 45−50.
[104]	Majnarić-Trtica L, Vitale B. Systems biology as a conceptual framework for research in family medicine; use in predicting response to influenza vaccination. Prim Health Care Res 2011; 12: 310−321. doi: 10.1017/S1463423611000089
[105]	Šabanović Š, Ljiljana MT, Babič F, et al. Metabolic syndrome in hypertensive women in the age of menopause: a case study on data from general practice electronic health records. BMC Med Inform Decis Mak 2018; 18: 24. doi: 10.1186/s12911-018-0601-2
[106]	Bekić S, Babič F, Filipčić I, et al. Clustering of mental and physical comorbidity and the risk of frailty in patients aged 60 years or more in primary care. Med Sci Monit 2019; 25: 6820−6835. doi: 10.12659/MSM.915063
[107]	Majnarić LT, Bekić S, Babič F, et al. Cluster analysis of the associations among physical frailty, cognitive impairment and mental disorders. Med Sci Monit 2020; 26: e924281. doi: 10.12659/MSM.924281.